Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-02-27 Interim / Quarterly Rep…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2022/2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 December 2022. It contains comprehensive financial data, including a consolidated income statement, a condensed consolidated balance sheet, a condensed consolidated cash flow statement, and selected notes to the financial statements. Since it covers a period shorter than a full fiscal year and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report (IR). Q2 2023
2023-02-27 German
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment
Regulatory Filings Classification · 100% confidence The document is a press release dated February 22, 2023, announcing a 'joint development agreement (JDA)' between BRAIN Biotech AG and TransCode Therapeutics regarding a CRISPR-derived technology platform for cancer treatment. It details a strategic partnership and future commercialization plans. This type of announcement, which details a significant business development, partnership, or strategic move that is not a standard periodic financial report (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a strategic agreement and not a standard financial report, dividend notice, management change, or capital action, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially 'M&A Activity' (TAR) if the partnership implied a merger, but here it is clearly a JDA. Given the options, RNS serves as the best general category for non-standard, material corporate news releases that don't fit the more specific codes like DIV, CAP, or MANG.
2023-02-22 English
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Freres
Regulatory Filings Classification · 98% confidence The document is dated February 10, 2023, is labeled as 'Ad-hoc' information, and explicitly states it is an 'Disclosure of an inside information acc. to Article 17 MAR'. This structure is typical of a mandatory regulatory disclosure concerning a significant corporate event (contract termination). Since it is not a standard periodic report (10-K, IR, ER) or a specific shareholder/management action (DIV, DIRS, DEF 14A), and it serves as a general, immediate regulatory announcement, the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings). The document length is short (under 4,000 characters) and it is an announcement, not the full report itself.
2023-02-10 English
Jahresabschluss zum Geschäftsjahr vom 01.10.2021 bis zum 30.09.2022
Interim / Quarterly Report Classification · 95% confidence The document contains a detailed balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and extensive notes (Anhang) for the fiscal year ending September 30, 2022, for BRAIN Biotech AG. It follows German HGB accounting standards and provides substantive financial data rather than just an announcement or certification. While it is a standalone financial report for the parent company (Jahresabschluss), it functions as an interim/annual financial disclosure. Given the definitions provided, it fits the 'Interim / Quarterly Report' (IR) category as it is a comprehensive financial report for a specific period containing actual financial statements. FY 2022
2023-02-03 German
Konzernabschluss zum Geschäftsjahr vom 01.10.2021 bis zum 30.09.2022
Annual Report Classification · 95% confidence The document contains detailed consolidated financial statements including balance sheet, income statement, statement of changes in equity, and cash flow statement for the fiscal year ending 30 September 2022. It also includes extensive notes on accounting policies and company background. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure correspond to a comprehensive annual financial report prepared under IFRS for a full fiscal year. There is no indication that this is merely an announcement or a certification. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2022
2023-02-03 German
BRAIN Biotech AG: Bekanntmachung der Einberufung zur Hauptversammlung am 08.03.2023 in Offenbach am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung' (Announcement of the Convocation to the General Meeting) and contains the full agenda ('Tagesordnung') for the meeting scheduled for March 8, 2023. The agenda items cover the presentation of the annual financial statements, discharge of the board and supervisory board, election of auditors, election of supervisory board members, and resolutions regarding capital authorization (convertible/option bonds). This content is the core material for convening a General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R), as it is the official notice and material for the Annual General Meeting.
2023-01-27 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.